SCHEMBL6575645

SCHEMBL6575645

CC(C)c1cccc(C(C)C)c1N[Si](C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.44
LMNA P02545 2/20 0.44
GABRG2 P18507 2/20 0.44
GABRB3 P28472 2/20 0.44
GABRB2 P47870 2/20 0.44
FAAH O00519 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
GABRB1 P18505 1/20 0.44
PTGS1 P23219 1/20 0.44
SLC6A2 P23975 1/20 0.44
HTR2C P28335 1/20 0.44
GABRA5 P31644 1/20 0.44
GABRA3 P34903 1/20 0.44
HTR2B P41595 1/20 0.44
GABRA2 P47869 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28481970 0.92 SMN1; SMN2 (0.42) GABRA1LMNAGABRG2GABRB3GABRB2
SCHEMBL22686863 0.76 GABRA1 (0.42) GABRA1GABRB2TDP1
SCHEMBL812723 0.75 GABRA1 (0.52) GABRA1LMNAGABRG2GABRB3GABRB2
SCHEMBL6180997 0.73 GABRA1 (0.50) GABRA1LMNAGABRG2GABRB3GABRB2
SCHEMBL17636899 0.71 SMN1; SMN2 (0.50) GABRA1LMNAGABRG2GABRB3GABRB2
SCHEMBL3116485 0.71 GABRA1 (0.48) GABRA1LMNAGABRG2GABRB3GABRB2
SCHEMBL8159500 0.71 SMN1; SMN2 (0.50) GABRA1LMNAGABRG2GABRB3GABRB2
SCHEMBL22767461 0.71 GABRA1 (0.54) GABRA1LMNAGABRG2GABRB3GABRB2
SCHEMBL3206761 0.71 GABRA1 (0.48) GABRA1LMNAGABRG2GABRB3GABRB2
SCHEMBL10037121 0.71 GABRA1 (0.48) GABRA1LMNAGABRG2GABRB3GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200369689-A1 Arylaminosilane Compound, Propylene Polymerization Catalyst And Preparation Thereof PETROCHINA COMPANY LIMITED (CN) 2020-11-26 US claimed
CN-111978346-A Arylamine silane compound, propylene polymerization catalyst, preparation and application thereof 中国石油天然气股份有限公司 2020-11-24 CN claimed
CN-111153931-A 2-pyridine methane imine tin (II) compound and preparation method and application thereof 山西大学 2020-05-15 CN claimed
EP-1092729-B1 POLYMERIZATION CATALYST, NOVEL TRANSITION METAL COMPOUND, AND POLYMERIZATION METHOD AND COPOLYMER USING THEM MITSUI CHEMICALS INC (JP) 2012-09-26 EP claimed
US-6703459-B1 ORGANIC TRANSITION METAL COMPLEXES HAVING SPECIFIC STRUCTURE, WHICH CAN FORM COPOLYMERS HAVING LINKAGE FORMED BY MIGRATION OF ACTIVE HYDROGEN OF UNSATURATED MONOMER MITSUI CHEMICALS, INC. (JP) 2004-03-09 US claimed
EP-1092729-A1 POLYMERIZATION CATALYST, NOVEL TRANSITION METAL COMPOUND, AND POLYMERIZATION METHOD AND COPOLYMER USING THEM Mitsui Chemicals, Inc. (JP) 2001-04-18 EP claimed
US-11700765-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2023-07-11 US disclosed
US-11535638-B2 Arylaminosilane compound, propylene polymerization catalyst and preparation thereof PETROCHINA COMPANY LIMITED (CN) 2022-12-27 US disclosed
US-11149349-B2 Process for the generation of thin silicon-containing films BASF SE (DE) 2021-10-19 US disclosed
US-20200369689-A1 Arylaminosilane Compound, Propylene Polymerization Catalyst And Preparation Thereof PETROCHINA COMPANY LIMITED (CN) 2020-11-26 US disclosed
CN-111978346-A Arylamine silane compound, propylene polymerization catalyst, preparation and application thereof 中国石油天然气股份有限公司 2020-11-24 CN disclosed
US-20200295281-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2020-09-17 US disclosed
US-20190309417-A1 PROCESS FOR THE GENERATION OF THIN SILICON-CONTAINING FILMS BASF SE (DE) 2019-10-10 US disclosed
EP-1080084-A2 PROCESS FOR EPOXIDATION OF ARYL ALLYL ETHERS THE DOW CHEMICAL COMPANY (US) 2001-03-07 EP disclosed
US-6087513-A REACTION OF ALLYL ARYL ETHER WITH HYDROGEN PEROXIDE IN THE PRESENCE OF TRANSITION METALS FOR OXIDATION THE DOW CHEMICAL COMPANY (US) 2000-07-11 US disclosed
WO-1999062894-A2 PROCESS FOR EPOXIDATION OF ARYL ALLYL ETHERS THE DOW CHEMICAL COMPANY (US) 1999-12-09 WO disclosed
EP-0218138-B1 NEW CATALYSTS PROCESS FOR THEIR PRODUCTION AND THEIR USE FOR EFFECTING METATHESIS OF OLEFINS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1989-01-11 EP disclosed
US-4727215-A Catalyst composition for effecting metathesis of olefins MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1988-02-23 US disclosed
US-4681956-A Catalyst composition for effecting metathesis of olefins MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1987-07-21 US disclosed
EP-0218138-A1 New catalysts process for their production and their use for effecting metathesis of olefins MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1987-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200295281-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES SOD1, L1CAM, MCM2 GABRA1 3760/4885LMNA 1184/4885GABRG2 2574/4885
US-11535638-B2 Arylaminosilane compound, propylene polymerization catalyst and preparation thereof RPS8, PARP8, PRMT8 GABRA1 3277/4885LMNA 1477/4885GABRG2 3923/4885
US-20200369689-A1 Arylaminosilane Compound, Propylene Polymerization Catalyst And Preparation Thereof RPS8, PARP8, PRMT8 GABRA1 3277/4885LMNA 1477/4885GABRG2 3923/4885
US-11700765-B2 Organic electroluminescent materials and devices SOD1, L1CAM, MCM2 GABRA1 3760/4885LMNA 1184/4885GABRG2 2574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.